This NDC is on FDA's drug shortage list (posted Jul 18, 2023)
Product Information
LIRAGLUTIDE 3-PAK 18 MG/3 ML is a generic product labeled by Teva Pharmaceuticals USA Inc., priced at $30.6324 per ML under NDC 00480366722. Its NADAC has been published 107 times since Sep 18, 2024.
FDA first approved this application on Jan 25, 2010. Its Orange Book therapeutic-equivalence code is AP1.
Strength
6 mg/mL
Manufacturer
Teva Pharmaceuticals USA Inc.NDC
00480366722
Classification
Generic
Dosage Form
INJECTION
Route
SUBCUTANEOUS
Effective Date
9/23/2026
Active Ingredients
LIRAGLUTIDEApproval Type
Authorized Generic (NDA)
FDA Application
NDA022341FDA Approved
1/25/2010
TE Code
AP1
On Market Since
6/24/2024
Pharmacological Classes
Price Statistics
The NADAC for LIRAGLUTIDE 3-PAK 18 MG/3 ML has been published 107 times since Sep 18, 2024, and over the history we have for it it has declined 58.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $30.6324 per ML |
|---|---|
| All-time high | $72.9945 (Dec 11, 2024) |
| All-time low | $30.6324 (Sep 23, 2026) |
| 52-week high | $54.5298 |
| 52-week low | $30.6324 |
| Median price | $54.5298 |
| Average price | $53.7345 |
| Largest weekly change | -10.6% (Feb 18, 2026) |
| Weeks tracked | 107 |
| Tracking since | Sep 18, 2024 |
Generic Alternatives
The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Teva Pharmaceuticals USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
liraglutide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
GLP-1 Receptor Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of LIRAGLUTIDE 3-PAK 18 MG/3 ML?
The current National Average Drug Acquisition Cost (NADAC) for LIRAGLUTIDE 3-PAK 18 MG/3 ML, manufactured by Teva Pharmaceuticals USA Inc., is $30.6324 per ML (NDC 00480366722), effective Sep 30, 2026.
How has the price of LIRAGLUTIDE 3-PAK 18 MG/3 ML changed over time?
Over the history we have for it, the NADAC for LIRAGLUTIDE 3-PAK 18 MG/3 ML has declined 58.0%. It has been tracked across 107 weekly CMS publications since Sep 18, 2024.
What are the highest and lowest recorded NADAC prices for LIRAGLUTIDE 3-PAK 18 MG/3 ML?
Since Sep 18, 2024, the NADAC for LIRAGLUTIDE 3-PAK 18 MG/3 ML has ranged from a low of $30.6324 (Sep 23, 2026) to a high of $72.9945 (Dec 11, 2024), with a median of $54.5298 per ML.
Are there cheaper alternatives to LIRAGLUTIDE 3-PAK 18 MG/3 ML?
4 manufacturers publish a NADAC-priced product with the same active ingredient and strength as LIRAGLUTIDE 3-PAK 18 MG/3 ML in a comparable dosage form, but none are currently priced below it.
Who manufactures LIRAGLUTIDE 3-PAK 18 MG/3 ML?
LIRAGLUTIDE 3-PAK 18 MG/3 ML (NDC 00480366722) is labeled by Teva Pharmaceuticals USA Inc., and CMS classifies it as a generic product.
Is LIRAGLUTIDE 3-PAK 18 MG/3 ML in shortage?
Yes — NDC 00480366722 is currently listed in FDA's drug shortage database (posted Jul 18, 2023).